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protein biomarkers are widely used in cancer diagnosis, prognosis, and prediction of treatment 
response. Here we introduce the use of targeted multiplex proteomics (tMp) as a tool to simultaneously 
measure a panel of 54 proteins involved in oncogenic, tumour suppression, drug metabolism and 
resistance, in patients with metastatic colorectal cancer (mcRc). tMp provided valuable diagnostic 
information by unmasking an occult neuroendocrine differentiation and identifying a misclassified 
case based on abnormal proteins phenotype. No significant differences in protein levels between 
unpaired primary and metastatic samples were observed. Four proteins were found differentially 
expressed in KRAS-mutant as compared to wild-type tumours (overexpressed in mutant: KRAS, eGfR; 
overexpressed in wild-type: TOPO1, TOP2A). Survival analyses revealed the association between 
mesothelin expression and poor overall survival, whereas lack of pten protein expression associated 
with lower progression-free survival with anti-EGFR-based therapy in the first-line setting for patients 
with RAS wild-type tumour. Finally, outlier analysis identified putative targetable proteins in 65% of 
patients lacking a targetable genomic alteration. our data show that tMp constitutes a promising, 
novel molecular prescreening tool in mcRc to identify protein expression alterations that may impact 
on patient outcomes and more precisely guide patient eligibility to clinical trials with novel targeted 
experimental therapies.
Simultaneous and accurate measurement of many proteins in experimental samples is very important in descrip-
tive and predictive biological research, including comprehensive proteomic surveys, protein network studies, 
validation of genomic alterations and clinical biomarker development.
The accepted ‘gold standard’ for protein measurement is immunoassay, which uses either one (as in immu-
nohistochemistry or IHC) or two (competitive immunoassays) antigen-specific antibodies. Antibody-antigen 
binding can be measured across multiple matrices such as in fluids, on the surface of cells, within cells or tissues 
and in organs. The most widely used platform for tissue-based biomarker analyses is IHC, which facilitates the 
qualitative expression of proteins while preserving tissue architecture. Despite being a relatively easy and inexpen-
sive approach, IHC has its limitations including reproducibility issues and very poor multiplexing capabilities. It 
is at best a semiquantitative method and is minimally effective for comprehensive analyses.
Targeted proteomics using selected reaction monitoring mass spectrometry (SRM-MS) has emerged as a 
promising and highly sensitive method for the quantification of multiple proteins within the same tissue sample 
in an antibody-free setting1–3. However, its application to formalin -fixed paraffin -embedded (FFPE) tissues, 
which represent the standard preservation method for tumour samples analysed in the clinic, has been hampered 
by incomplete solubilization of samples4,5.
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In the present study, we used the Liquid Tissue® proteomic method to reverse formalin-induced crosslinks 
allowing complete solubilization of all proteins in the sample for the precise quantification6,7. The reliability of 
this approach for the analysis of proteins in patient tumour tissues has been previously demonstrated8–13. Our tar-
geted panel of proteins including oncogenic, tumour suppression, drug metabolism, and drug resistance markers, 
among others were measured in FFPE tissues from 50 patients with mCRC treated at our institution and whose 
tumours were genomically-profiled as a prescreening strategy for clinical trial recruitment. We performed an 
exploratory correlative analysis of protein levels with clinicopathological and genomic markers, investigated their 
association with the patient outcome – including response to standard chemotherapies and combinations with 
anti-EGFR agents – and assessed their potential as predictive biomarkers for novel targeted experimental thera-
pies currently under investigation.
Results
exploratory expression analysis of targeted multiplex proteomics in mcRc. Clinicopathological 
characteristics of patients included in our study are summarized in Table 1 (Supplementary Table 1 for indi-
vidual data). All patients consented to participate in a molecular prescreening programme that included tar-
geted next-generation sequencing and MET amplification status by fluorescence in situ hybridization to identify 
potentially targetable alterations. FFPE blocks were retrieved from the pathology archive of the Vall d’Hebron 
University Hospital.
Age, median (range) years 57.9 (28–73)
Sex
Male 32 (64%)
Female 18 (36%)
Location
Left colon 31 (62%)
Right colon 7 (14%)
Rectum 7 (14%)
NA 5 (10%)
Metastatic sites at diagnosis
0 17 (34%)
>0 33 (66%)
RAS status
KRAS Mutated 20 (40%)
NRAS Mutated 1 (2%)
RAS Wild-type 29 (58%)
PIK3CA status
Mutated 6 (12%)
Wild-type 44 (88%)
Tissue
Primary 26 (52%)
Liver metastasis 24 (48%)
First-line chemotherapy
Irinotecan + 5FU 14 (28%)
Oxaliplatin + 5FU 16 (32%)
Oxaliplatin + 5FU + anti-EGFR 8 (16%)
Irinotecan + 5FU + anti-EGFR 9 (18%)
Other 3 (6%)
Second-line chemotherapy
Irinotecan + 5FU 22 (44%)
Oxaliplatin + 5FU 5 (10%)
Oxaliplatin + 5FU + anti-EGFR 2 (4%)
Irinotecan + 5FU + anti-EGFR 13 (26%)
anti-EGFR alone 1 (2%)
Not given 7 (14%)
Survival, median (95% confidence interval) months
Survival metastatic setting 44.3 (40–58)
Time to progression first-line 8.3 (7–11)
Time to progression second-line 6.9 (6–9)
Table 1. Patients’ characteristics.
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Figure 1. Targeted multiplex proteomics heatmap. Individual samples are plotted in columns (case IDs are 
indicated at the bottom of each column). Proteins are plotted in rows. Each cell shows the protein level in amol/
μg. For each protein, levels of expression are shown on a colour scale from the lowest (light grey) to the highest 
(red) value. ND indicates non-detectable levels. Percentage of ND for each protein is shown in the rightmost 
column. RAS and PIK3CA status (MUT, mutation; WT, wild type), tissue (PRIM, primary sample; MET, 
metastasis), and site are indicated; NA: not applicable.
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To obtain a pure population of tumour cells without the surrounding microenvironment, we performed 
laser-capture microdissection. Isolated tumour cells were then solubilized to tryptic peptides using Liquid 
Tissue® technology as previously described10. All samples were qualified as evaluable according to the expression 
levels of the two housekeeping proteins actin and tubulin. We based the selection of the target proteins included 
in our TMP panel on a literature search for predictive biomarkers of response to targeted/chemo/immunotherapy 
and also included differentiation proteins with diagnostic value. Among 54 target proteins analysed, 18 (33%) 
were below the limit of detection of SRM-MS (non-detectable) (Supplementary Table 2). FGF receptors (FGFR1-
3), IGF1R, HGF, and PDL1 were among non-detectable proteins. Thirty-six proteins (67%) were detectable in 
at least one sample. Levels of expression (amol/μg) of detectable proteins for each individual patient are shown 
in Fig. 1 as heatmaps (see also supplementary figure 1 for aggregated data). The threshold for the definition of 
high protein expression varied by protein. We used predefined criteria when supporting literature was available: 
≥4,000 amol/μg for EGFR14, ≥750 amol/μg for HER211,13 and ≥1500 amol/μg for cMET12. These thresholds were 
shown to be predictive of protein overexpression and/or gene amplification detected by standard IHC and fluo-
rescence in situ hybridization. For the remaining ones, SRM-MS levels above the upper 95% confidence interval 
of the mean were defined as high expression (Supplementary Table 3).
The TMP panel included 7 proteins routinely used in diagnostic IHC including cytokeratins (KRT5 and 
KRT7), markers of stratified epithelia (P63), mesenchymal (Vimentin) and neuroendocrine (CHGA, SYP) differ-
entiation, and primary tumour origin (TTF1). Analysis of differentiation markers showed a lack of expression of 
P63 and TTF1 in all but 2 cases (4%), consistent with the colorectal origin of our samples. One tumour (ID-87) 
with P63 expression also showed very high levels of EGFR and KRT5, highly suggestive of squamous cell differen-
tiation. Upon histopathological review, the case turned out to be an anal squamous cell carcinoma and, therefore, 
excluded from further analyses. The only case in our dataset expressing TTF1 was a liver metastasis (ID-51). 
Thyroid transcription factor 1 (TTF1) has been considered a highly sensitive and specific marker for primary 
lung adenocarcinoma. As it is not usually expressed in CRC, TTF1 is used for the differential diagnosis of meta-
static adenocarcinomas of colorectal versus lung origin15,16. The subsequent IHC workup on ID-51 showed strong 
TTF1 nuclear positivity, KRT20 positivity and KRT7 negativity, a profile pointing to colorectal origin, which was 
supported by clinical assessment. Five tumours showed detectable levels of CHGA, a marker of neuroendocrine 
differentiation. IHC analyses confirmed the presence of CHGA positive cells in otherwise conventional adenocar-
cinomas of the colon, and outlined an occult neuroendocrine differentiation in one case (ID-08) with very high 
levels (10-times higher than those of the lowest detectable case) (Supplementary Figure 2A).
Since samples from both primary tumours (n = 25) and metastatic disease (n = 24) were included in our 
cohort, we investigated differences in protein expression levels according to the tissue of origin. Overall, no sig-
nificant difference between unpaired primary and metastatic lesions was observed (BH adjusted Mann-Whitney 
p > 0.05 for all comparisons) (Supplementary Table 4). When dichotomized (detectable vs non-detectable), 
KRT7 was found expressed in 19% of primaries and 71% of metastatic samples (Pearson’s Chi-squared p = 0.003). 
Confirmatory IHC analyses showed that KRT7 expression prevailed in tumour buds present in both primary and 
metastatic samples as has been previously described17. Worthy of note, entrapped normal epithelial cells from the 
lung were the main contributor of KRT7 expression in sample ID-53 (Supplementary Figure 2B).
protein expression in RAS-mutated and wild-type tumours. Understanding that RAS mutation is a 
validated stratification factor in mCRC, we then examined differences in proteins levels in RAS-mutated (n = 21, 
43%) versus wild-type cases (n = 28, 57%). KRAS and EGFR expression levels were higher in the RAS-mutated 
subgroup as compared to wild-type (BH adjusted Mann-Whitney p = 0.023 for both comparisons). Median 
KRAS expression levels were 1192 amol/μg (IQR 1011-1327) and 867 amol/μg (IQR 640-1006) for RAS-mutated 
and wild-type tumours, respectively (no differences were found according to codon mutated). Median EGFR 
expression levels were 232 amol/μg (IQR 210-299) in RAS-mutated and 192 amol/μg (IQR 165-206) in wild-type 
tumours. On the other hand, TOPO1 and TOP2A were significantly underexpressed in RAS-mutated tumours 
(BH adjusted Mann-Whitney p = 0.023 for both comparisons). Median TOPO1 expression levels were 1408 
amol/μg (IQR 1116-1893) and 1033 amol/μg (IQR 953-1131) for RAS wild-type and mutated tumours, respec-
tively. TOP2A levels were 753 amol/μg (IQR 492-936) in RAS wild-type and 441 amol/μg (IQT 354-587) in 
mutated tumours (Supplementary Table 5).
Targeted multiplex proteomics identifies MSLN as a prognostic marker in mCRC. We assessed the 
prognostic value of protein expression levels in terms of overall survival (OS) in the metastatic setting. In univariate 
analysis, after multiple testing adjustment, only MSLN levels associated with outcome (Log-Rank test, p = 0.004; 
Fig. 2A, Supplementary Table 6). We found MSLN expression (SRM-MS > 0) in 15 out of 49 cases (30%) of mCRC 
by SRM-MS. In a multivariate analysis, MSLN remained an independent factor predicting worse OS in the metastatic 
setting (Cox proportional-hazard test, p = 0.04; Supplementary Table 7). Interestingly, MSLN expression levels were 
comparable with those found in one control mesothelioma included in the analysis (748.5 amol/μg, data not shown).
To confirm proteomics-driven results and determine which cell type was expressing MSLN in the context of 
CRC, we compared expression results generated by SRM-MS with standard IHC. All but 3 samples previously 
profiled with SRM-MS could be analysed with IHC. A strong correlation between SRM-MS and IHC as contin-
uous MSLN expression values was found (Spearman’s rank correlation coefficient 0.669, p < 0.0001, Fig. 2B). 
When dichotomizing for positive versus negative cases, we observed an overall concurrence of 83% between the 
two approaches (Fisher test, p = 0.0001). MSLN expression was observed mainly at the tumour cell membrane 
but also in the cytoplasmic compartment (Fig. 2C). There was no association between MSLN expression by either 
SRM-MS or IHC and tumour stage at diagnosis (III vs IV), sample origin (primary versus metastasis), primary 
tumour location, and RAS mutation status (Supplementary Figure 3A). High levels of MSLN were associated with 
worse OS independently of the methodology used (Supplementary Figure 3B).
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Protein expression as a predictor of clinical benefit with targeted and standard therapies. A 
total of 23 RAS wild-type patients received an anti-EGFR therapy as first or second line of treatment. Lack of 
PTEN protein expression significantly associated with a high risk of progression in the first-line anti-EGFR set-
ting, with a time to progression of 4.2 months versus 9.4 months in patients whose tumours expressed PTEN 
(HR = 3.7, CI95% 1.1–13.1, p = 0.03). No association between other protein expression levels (including EGFR) 
and response to EGFR targeted therapy was found.
Figure 2. Mesothelin (MSLN) expression in colorectal cancer. (A) Kaplan-Meier analysis of overall survival 
in the metastatic setting according to MSLN expression levels quantified by mass spectrometry (MS). (B) 
Correlation between MS (x-axis, amol/ug) and immunohistochemistry (y-axis, H-score). Pearson correlation 
coefficient, 95% confidence interval and p-value are indicated. (C) Representative immunohistochemistry 
staining of a MS MSLN-negative (upper panel; ID-79, liver metastasis, H-score = 0) and –positive (lower panel; 
ID-72, primary CRC, H-score = 210) cases. Digital magnification: 0.5 × (left) and 20 × (right).
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A panel of 19 proteins involved in chemosensitivity or chemoresistance was analysed in our TMP assay. 
Among those, thymidylate synthase (TS), excision repair cross-complementing group 1 (ERCC1), and 
Topoisomerase 1 (TOPO1) have been previously studied as putative biomarkers of response to 5-FU, oxalip-
latin, and irinotecan, respectively18–22. In our dataset, TS was detectable in a single case (2%) whereas ERCC1 
and TOPO1 were expressed in 22% and 100% of mCRC analysed (6% and 28% at high levels, respectively). 
No association between ERCC1 and benefit from treatment with oxaliplatin-based chemotherapy was found 
(n = 28 eligible patients, Pearson’s Chi-squared p-value = 0.62). Similarly, we did not find a significant associa-
tion between clinical benefit from irinotecan-based therapy and TOPO1 expression when dichotomized at the 
high-level cut-off (n = 44 eligible patients, Pearson’s Chi-squared test p = 1).
protein expression signposts treatment selection in early clinical trials. One of the major goals 
of our study was to explore whether multiplex proteomic analysis could complement current genomic molecular 
prescreening by identifying abnormal proteins expression in patients without any targetable genomic alteration. 
Out of 49 patients, 6 (12%) had PIK3CA exon 9 or 20 mutations (all but one case with a co-existing KRAS muta-
tion) eligible for combination therapy with PI3K inhibitors at our institution.
In the remaining 43 patients without targetable genomic alteration, SRM-MS identified 20 patients (47%) with-
out PTEN expression (non-detectable), enrichment criteria for PI3K pathway inhibitors. In addition, 1 tumour 
had very high expression of EGFR (7635 amol/μg) and 4 harboured high expression levels of HER2 (confirmed 
by standard IHC, Supplementary Figure 2C). This could guide enrollment in clinical trials with novel HER family 
inhibitors. No patient had high cMET protein expression (in line with the lack of MET amplification by fluores-
cence in situ hybridization in our cohort). With regards to other proteins measured in our TMP panel, in the 
absence of a validated threshold for overexpression by SRM-MS, we conducted Robust regression and Outlier 
removal (ROUT) analysis23 (false discovery rate of 1%). A total of 31 outliers (proteins expressed at very high levels) 
across 12 proteins were identified in 24 individual patients (Supplementary Figure 4). Twenty-nine (93.5%) outliers 
were found in 21 patients without any targetable genomic alteration. Among these, 12 could be potentially used 
to guide the selection of an investigational antibody-drug conjugate treatment (GPNMB, MSLN, and TROP2) or 
refine a chemotherapy strategy (TOPO1 and TOP2A). Overall, 28 out of 43 patients (65%) whose tumours lacked 
a genomic match to a clinical trial were eligible for investigational drugs as a result of TMP analysis (PTEN, EGFR, 
HER2, GPNMB, MSLN, TROP2, TOPO1 or TOP2A as emerging positive predictive markers) (Fig. 3).
Discussion
Therapies guided by tumour molecular profiling have shown significant clinical benefit in treating patients with 
advanced cancer. In mCRC, examples of emerging markers include BRAFV600E mutations24, HER2 overexpression/
amplification25,26, and MET amplification27. However, in aggregate, these predictors are positive in less than 10% of 
mCRC population, indicating the need for more informative molecular screening approaches. Similarly, the decision 
to administer standard chemotherapies in the metastatic setting (e.g. FOLFOX or FOLFIRI) remains empirical and 
does not rely on tumour biomarkers, which could be revealed by a novel multiplatform profiling strategy like ours.
To the best of our knowledge, this is the first study to explore the potential impact of quantitative targeted 
proteomics in the context of precision oncology in mCRC. A comprehensive molecular profiling of CRC sam-
ples has been previously conducted with a multiplatform approach that includes sequencing, IHC, fluorescence 
in situ hybridization and chromogenic in situ hybridization to investigate targetable biomarker aberrations28. 
Authors found major differences in the expression of selected proteins across different metastatic sites, reflecting 
inter-metastatic tumour heterogeneity, although the limited overlap in term of proteins analyzed (only 15 in 
total) and the different methodology used for protein expression (IHC vs SRM-MS in our study) hampered any 
comparative analysis.
In our study, we investigated quantitative protein biomarker profiles of mCRC and integrated the results 
obtained with available clinical, pathological and genomic data towards advancing insights into predictive 
and prognostic markers. Our TMP panel included proteins involved in oncogenic, tumour suppression, drug 
metabolism and resistance as well as tumour differentiation markers that could aid in the standard diagnostic 
Figure 3. Distribution of genomic targetable alterations (inner circle). Detailed proteomic targetable alterations 
for non-genomics targetable samples (outer ring).
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decision-making processes as well as the selection of novel targeted drugs and immunotherapies (antibody-drug 
conjugates or ADC).
The major impact of the use of TMP in mCRC may translate in more precisely matching patients to experi-
mental therapies. Recruitment rates in early clinical trials based on genomic markers or targeted IHC in meta-
static CRC does not exceed 15%29,30. We expect that proteomics-guided drug development will expand treatment 
options for patients who are eligible to participate in early phase clinical studies, particularly in view of the 
increasing array of ADCs and immunotherapeutic approaches, thus repurposing proteomics as an important 
contender in precision oncology.
Until validated thresholds for individual biomarkers become available, outlier expression may be a valuable 
marker for testing novel experimental therapies in the metastatic setting as well as an enrichment strategy for 
clinical trials. In our present study, we found 29 outliers in 21 patients without any targetable genomic alteration, 
12 of which are potentially useful in more precisely guiding the selection of an investigational ADC therapy 
(GPNMB, MSLN, and TROP2) or refining a chemotherapy strategy (TOPO1 and TOP2A).
With regards to novel prognostic markers and therapeutic targets, our TMP analysis identified MSLN expres-
sion in 30% of metastatic CRC. MSLN is a cell-surface glycoprotein whose expression in normal human tissues 
is restricted to mesothelial cells. Given that it is highly expressed by many solid tumours (mesotheliomas, pan-
creatic, gastric and ovarian cancers among others), it represents an attractive target for ADC development31. In 
mCRC, the value of MSLN expression has not been thoroughly investigated. The prognostic association we found 
between MSLN and poor prognosis has been previously reported in the literature with both tumour and plasma 
MSLN levels in early-stage CRC32,33 thus strengthening the role of this protein in CRC biology. This supports its 
investigation as a therapeutic target in this yet unexplored tumour indication.
We also investigated the value of TMP in patient selection for standard-of-care targeted agents. We recognize 
the difficulties in identifying predictive markers for anti-EGFR and standard therapies in our cohort since these 
therapies are administered in combination regimens and the small sample size that together do not allow for the 
proper study of interactions among different markers and therapies. We did, however, identify an association 
between a lack of PTEN protein expression and shorter time to progression in the first-line setting with chemo-
therapy plus anti-EGFR in RAS wild-type patients. Previous retrospective studies34–37 showed that this association 
could well be linked to a prognostic effect of PTEN in this subset of patients38,39 as opposed to a predictive value40.
Exploratory analysis of proteomics data allowed us to assess the value of complementary data provided by 
this approach in the context of the molecular diagnostic evaluation of mCRC patients. First, TMP may assist in 
refining conventional histopathological diagnosis, identifying misdiagnosed cases, and revealing uncommon dif-
ferentiation that may help clinicians to prioritize alternative treatment regimens. For example, we could confirm 
an occult neuroendocrine differentiation in one case as well as an atypical proteomics profile which facilitated 
the identification of a patient sample erroneously submitted as colorectal adenocarcinoma for molecular analy-
ses. Second, primary tumour molecular profiling is generally used for treatment decision even in the metastatic 
setting where cancer may have acquired new alterations or lost those originally present during carcinogenesis. 
Our analysis failed to reveal significant differences in protein expression levels between unmatched primary and 
metastatic samples (continuous protein levels), thus supporting current profiling strategies at least for the tar-
gets included in our panel. Finally, comprehensive proteomics analysis may also expose biological differences 
in clinically or molecularly-defined groups. We examined differences in the biomarker profiles based on RAS 
mutation status. KRAS protein levels were significantly higher in RAS mutant vs wild-type CRC, independently 
of the mutation type. This is not surprising as KRAS mutations occurring in codons 12 and 13 of exon 2 induce 
stabilization of the protein in a constitutive activation state which, in theory, could also facilitate the detection of 
higher levels of the total protein in mutant tumours as compared to wild-type41. We also found that TOPO1 and 
TOP2A expression levels were lower in RAS-mutated tumours, an association not previously reported in the liter-
ature, and that reinforces differences in the biology of these tumours. Higher TOPO1 expression in RAS wild-type 
may favour irinotecan over oxaliplatin in this molecular subgroup, and many trials are assessing irinotecan plus 
anti-EGFR therapy re-challenge after an initial response in RAS wild-type mCRC. Similarly, high TOP2A levels 
may suggest an increased sensitivity to topoisomerase II inhibitors42,43 in RAS wild-type CRC and prompt the 
exploration of agents not routinely considered as standard-of-care. These results certainly merit further consid-
eration in future clinical trials.
In conclusion, this study opens the door to the application of targeted multiplex proteomics in CRC with a potential 
impact on patient stratification for precision medicine. Our results reinforce the inter-tumour heterogeneity of CRC 
with unique protein alterations in individual cases that can guide enrolment in early clinical trials and co-development 
of biomarkers and drugs. We expect that an expanded TMP panel with proteins that represent targets for ADCs and 
immune checkpoints may bring novel insights on potential combinatorial immunotherapeutic strategies.
Methods
patient selection. Samples of histologically confirmed invasive CRC diagnosed at Vall d’Hebron University 
Hospital (Barcelona, Spain) were retrospectively identified by a study pathologist. All patients included in the 
study underwent a molecular prescreening between 2013 and 2014 which included an amplicon sequencing 
analysis of a panel of 59 genes44 and MET amplification status by fluorescence in situ hybridization. The protocol 
of this study was approved by the Vall d’Hebron University Hospital Ethical Committee (PR(AG)147-2009) and 
all methods were performed following relevant guidelines and regulations. Informed consent was obtained from 
all patients. Clinicopathological characteristics are shown in Table 1 and Supplementary Table 1.
SRM-MS analysis. Proteins were quantitated by SRM-MS as previously described7,10. Briefly, tissue sections 
(10 μM) were cut from FFPE blocks, placed onto Director® microdissection slides, deparaffinized and stained 
with haematoxylin. Tumour areas were marked by a board-certified pathologist. Microdissection of the marked 
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area was performed using a laser microdissector (Molecular Machines, Germany). A total area of 12 mm2 contain-
ing approximately 45,000 malignant cells was microdissected from each tumour and transferred directly into the 
cap of 0.65 ml tube containing 20 µl of 100% acetonitrile. Acetonitrile was removed by SpeedVac centrifugation at 
35 °C for 6 min. The dried dissection pellet was stored at −20 °C. Peptides were extracted from the pellet using the 
Liquid Tissue® technology as per manufacturer’s instructions (Expression Pathology, NantOmics, Rockville, MD, 
available for purchase at NantOmics). The Liquid Tissue® protocol involves heating the tumour tissue at 95 °C for 
90 minutes using the Liquid Tissue® buffer, followed by trypsin digestion for 18 hours at 37 °C. The resulting pep-
tide concentration is measured by the microBCA assay. Heavy labelled internal standards are added along with 
buffer A (0.1% formic acid). 10 µl of this mixture is injected into the mass spectrometer (Thermo TSQ Quantiva) 
and a targeted list of peptides (see Supplementary Table 2 for targets included in the panel) are quantitated using 
selected reaction monitoring. On-column injection results in 1 µg (~4000 cells) of solubilized tissue and 5 fmol of 
an internal standard. Normalization was conducted across all samples based on the total amount of protein. Data 
analysis was carried out using Pinnacle (Optys Tech, MA). For QC purposes, the levels of actin or tubulin had 
to be greater than 298 amol/µg or 28 amol/µg respectively in all samples. Instrumental analyses were performed 
on TSQ series (Vantage or Quantiva) of triple quadrupole mass spectrometer (Thermo Scientific, San Jose, CA).
Assay development and QC was along the lines of our previously published work12. Briefly, tryptic digestion 
of recombinant proteins, fixed cell lines or tissue was conducted. The peptides from recombinant proteins were 
first injected into the triple quadrupole mass spectrometer to identify the peptide characteristics (retention time, 
transition ion ratios, and area under the curve). This information was used to identify the peptides from fixed cell 
lines or FFPE tissue samples. The top two (based on AUC, reproducibility) unique peptides from FFPE or fixed 
cell lines were chosen for further development. Unlabelled and labelled synthetic peptides of the top two unique 
peptides were used to assess the analytical performance (LoD, LoQ, precision, and carryover). Eventually, the 
peptide that had the best analytical performance was used to quantitate the protein of interest.
immunohistochemistry. The following primary monoclonal antibodies were used: anti-chromogranin A 
(CHGA), anti-cytokeratin 7 (KRT7), anti-HER2, and anti-mesothelin (MSLN). Before cutting, paraffin blocks 
were cooled to −10 °C and 3 µm sections were cut with a microtome. To ensure tissue straightening, sections 
were floated on distilled water at 43 °C. Cut tissues were collected on positively charged Superfrost glass slides 
and slides were dried overnight at 37 °C. Immunohistochemical stainings of HER2, KRT7 and CHGA were per-
formed using a Benchmark ULTRA autostainer (Ventana Medical Systems, Tucson AZ). The slides were heated in 
the instrument and deparaffinized with EZ prep solution (Ventana Medical Systems, Tucson AZ). Heat-induced 
antigen retrieval was executed using Cell Conditioning 1 (CC1; Ventana Medical Systems, Tucson AZ) for 36 min 
at 95 °C. Then, the primary antibody was applied as indicated in Supplementary Table 8. Reactions were detected 
using the UltraView Universal DAB Detection kit (#760–500; Ventana Medical Systems, Tucson AZ). Finally, the 
slides were counterstained with Haematoxylin II and Bluing Reagent (Ventana Medical Systems, Tucson AZ) and 
mounted with xylene-based mounting medium.
Staining of MSLN was carried out using the rabbit Envision-kit (#K4003; DAKO/Agilent, Santa Clara, CA). 
Briefly, the sections were deparaffinized with xylene, dehydrated with decreasing ethanol baths and hydrated with 
distilled water and then heated in the PTLink for 20 minutes at 95 °C with Dako Target Retrieval Solution pH 9 
(#S2367; DAKO/Agilent, Santa Clara, CA), diluted 1:10 with distilled water. Endogenous peroxidase activities 
were inactivated with Dako Envision Flex Peroxidase Blocking Reagent for 15 min at room temperature and 
then protein block (#X0909; DAKO/Agilent, Santa Clara, CA) was applied for 30 minutes at room temperature. 
Samples were then incubated with rabbit anti-human MSLN monoclonal antibody (clone SP74) at room temper-
ature for 1 hour (dilution 1:2 with Dako REAL Ab Diluent #S2022; DAKO/Agilent, Santa Clara, CA). Flex HRP 
was then applied for 30 min at room temperature, followed by incubation with Dako DAB detection solution 
FLEX-DAB for 5 minutes at room temperature. Slides were counterstained with Merck Haematoxylin Harris 
(dilution 1:4) for 2 min, dehydrated and mounted with Xylol based mounting medium. IHC stained slides were 
scanned using NanoZoomer 2.0-HT (Hamamatsu Photonics, Japan) and subsequently, the digital images were 
scored by a pathologist blinded to the MSLN SRM-MS results. For the assessment of MSLN, a semi-quantitative 
approach was used in which H-scores were generated by multiplying the staining intensity (0 = no staining, 
1 = weak, 2 = moderate, 3 = strong) by the percentage of positive cells (0-100%). MSLN staining was considered 
positive when at least 15% of the cells showed moderate (2+) to strong (3+) intensity.
Statistical analysis. A descriptive analysis of the variables included in the study was performed. Continuous 
variables were expressed as median and IQR, and categorical variables were expressed as absolute values and 
percentages. Comparison of continuous variables was performed with non-parametric Mann-Witney test (two 
groups) or Kruskal-Wallis test (more than two) with adjustment for multiple testing according to Benjamini and 
Hochberg (BH) method. Spearman’s rank correlation coefficient was used to study the association between two 
continuous variables. For the univariate analysis of categorical variables, we used the Chi-squared test or Fisher 
exact test if cell frequencies were below 5. To assess their association with clinical benefit with standard chemo-
therapies, we classified patients as responders when the time to progression (calculated from the date of treatment 
initiation to progression or death) in the first-line or second-line treatments exceeded their respective medians 
(8.3 and 6.9 months, respectively).
Overall survival (OS) in the metastatic setting as an interval from the diagnosis of metastasis to death. Survival 
analysis was calculated using the Kaplan–Meier method and the log-rank test was used for statistical comparison. 
Hazard ratios (HRs) and associated 95% confidence interval were assessed using Cox proportional-hazard. ROUT 
analysis with a false discovery rate of 1% was conducted to identify outliers. Statistical significance was accepted at the 
conventional two-sided p < 0.05 threshold. The data analyses were carried out using R version 3.3.3 statistical software 
package.
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Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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